Evidence map›Paper›PMID 23689285›Full record

ArticleMolecular & cellular proteomics : MCP2013

Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS (LC-MRM-MS).

Susan E Abbatiello, D R Mani, Birgit Schilling, Brendan Maclean, Lisa J Zimmerman, Xingdong Feng, Michael P Cusack, Nell Sedransk, Steven C Hall, Terri Addona and 37 more

Abstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. A framework for quality control in quantitative proteomics.bioRxiv : the preprint server for biology · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors.

Susan E AbbatielloBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA. susana@broad.mit.edu
D R Mani
Birgit Schilling
Brendan Maclean
Lisa J Zimmerman
Xingdong Feng
Michael P Cusack
Nell Sedransk
Steven C Hall
Terri Addona
Simon Allen
Nathan G Dodder
Mousumi Ghosh
Jason M Held
Victoria Hedrick
H Dorota Inerowicz
Angela Jackson
Hasmik Keshishian
Jong Won Kim
John S Lyssand
C Paige Riley
Paul Rudnick
Pawel Sadowski
Kent Shaddox
Derek Smith
Daniela Tomazela
Asa Wahlander
Sofia Waldemarson
Corbin A Whitwell
Jinsam You
Shucha Zhang
Christopher R Kinsinger
Mehdi Mesri
Henry Rodriguez
Christoph H Borchers
Charles Buck
Susan J Fisher
Bradford W Gibson
Daniel Liebler
Michael Maccoss
Thomas A Neubert
Amanda Paulovich
Fred Regnier
Steven J Skates
Paul Tempst
Mu Wang
Steven A Carr

Funding

TrainingP41GM103533 · NIGMS · UNIVERSITY OF WASHINGTON · PI MACCOSS, MICHAEL · 2012 to 2021
$20.7M
Proteo-genomic Discovery, Prioritization and Verification of Cancer BiomarkersU24CA160034 · NCI · BROAD INSTITUTE, INC. · PI CARR, STEVEN A, PAULOVICH, AMANDA G · 2011 to 2016
$16.2M
Measuring Cancer Biomarker Candidates by Targeted MS and Ab EnrichmentU24CA126476 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CARR, STEVEN A · 2006 to 2010
$14.6M
Assessment of serum peptide profiling to detect cancer-specific patternsU24CA126485 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI TEMPST, PAUL · 2006 to 2010
$8.0M
Skyline Targeted Proteomics EnvironmentR01GM103551 · NIGMS · UNIVERSITY OF WASHINGTON · PI MACCOSS, MICHAEL · 2012 to 2020
$3.4M
Self Correcting Nanoflow LC-MS for Clinical ProteomicsR01GM107142 · NIGMS · UNIVERSITY OF WASHINGTON · PI MACCOSS, MICHAEL · 2013 to 2016
$1.5M
4000 Q TRAP TRIPLE QUADRUPOLE/LINEAR ION TRAP LC/MS/MS: NEUROSCIENCE PARKINSON'SS10RR021222 · NCRR · BUCK INSTITUTE FOR AGE RESEARCH · PI GIBSON, BRADFORD WAYNE · 2005 to 2005
$500k
NCI NIH HHS U24 CA126476NCI NIH HHS U24 CA126485NCI NIH HHS U24 CA160034NCRR NIH HHS S10 RR0021222.NCRR NIH HHS S10 RR021222NIGMS NIH HHS P41 GM103533NIGMS NIH HHS R01 GM103551NIGMS NIH HHS R01 GM107142PHS HHS U24 126477PHS HHS U24 126479PHS HHS U24 126480
6 · The paper itself

Abstract

Multiple reaction monitoring (MRM) mass spectrometry coupled with stable isotope dilution (SID) and liquid chromatography (LC) is increasingly used in biological and clinical studies for precise and reproducible quantification of peptides and proteins in complex sample matrices. Robust LC-SID-MRM-MS-based assays that can be replicated across laboratories and ultimately in clinical laboratory settings require standardized protocols to demonstrate that the analysis platforms are performing adequately. We developed a system suitability protocol (SSP), which employs a predigested mixture of six proteins, to facilitate performance evaluation of LC-SID-MRM-MS instrument platforms, configured with nanoflow-LC systems interfaced to triple quadrupole mass spectrometers. The SSP was designed for use with low multiplex analyses as well as high multiplex approaches when software-driven scheduling of data acquisition is required. Performance was assessed by monitoring of a range of chromatographic and mass spectrometric metrics including peak width, chromatographic resolution, peak capacity, and the variability in peak area and analyte retention time (RT) stability. The SSP, which was evaluated in 11 laboratories on a total of 15 different instruments, enabled early diagnoses of LC and MS anomalies that indicated suboptimal LC-MRM-MS performance. The observed range in variation of each of the metrics scrutinized serves to define the criteria for optimized LC-SID-MRM-MS platforms for routine use, with pass/fail criteria for system suitability performance measures defined as peak area coefficient of variation <0.15, peak width coefficient of variation <0.15, standard deviation of RT <0.15 min (9 s), and the RT drift <0.5min (30 s). The deleterious effect of a marginally performing LC-SID-MRM-MS system on the limit of quantification (LOQ) in targeted quantitative assays illustrates the use and need for a SSP to establish robust and reliable system performance. Use of a SSP helps to ensure that analyte quantification measurements can be replicated with good precision within and across multiple laboratories and should facilitate more widespread use of MRM-MS technology by the basic biomedical and clinical laboratory research communities.

Indexed as

Amino Acid SequenceAnimalsCattleChromatography, LiquidLimit of DetectionMass SpectrometryMolecular Sequence DataPeptidesReference StandardsSoftwareTime FactorsPeptides

Identifiers

PMID23689285
PMCPMC3769335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.